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Ceftriaxone is a commonly used antibiotic due to some of its advantages. Reversible gallbladder (GB) sludge or stone has 
been reported after ceftriaxone therapy. Most of these patients have no symptom, but the GB sludge or stone can sometimes 
cause cholecystitis. We experienced two patients who had newly developed GB stones after ceftriaxone therapy for divertic-
ulitis and pneumonia, and this resolved spontaneously 1 month after discontinuation of the drug. Awareness of this compli-
cation could help to prevent unnecessary cholecystectomy.
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INTRODUCTION
Ceftriaxone is one of the most commonly used 3rd gen-
eration parenteral cephalosporins because it has wide 
spectrum of anti-microbial activity, a long plasma half-life 
that allows once-daily administration and it can even pen-
etrate the blood brain barrier [1]. Ceftriaxone could have 
potential complications and these are biliary sludge or 
biliary lithiasis, and even urinary tract precipitation [2,3], 
but these complication may be reversible upon dis-
continuation of ceftriaxone [2]. We present here two cases 
of newly developed gallbladder (GB) stone after usage of 
ceftriaxone and the GB stone disappeared after dis-
continuation of the drug.
CASE REPORTS
Case 1
A 21- year-old man who had no medical history was ad-
mitted to the hospital due to lower abdominal pain that he 
had for 1 day. Physical examination revealed direct ten-
derness on the right lower quadrant without rebound 
tenderness. The laboratory evaluation was within the nor-
mal range except mild leukocytosis. Computed tomog-
raphy (CT) showed cecal diverticulitis and there was no 
evidence of stone in the GB (Fig. 1A). Five days of intra-
venous ceftriaxone (2 g i.v. q 24 hours) was administered 
for controlling the diverticulitis, and consequently the 
pain was much improved. The follow-up CT, which was Yoon Young Choi, et al.
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Fig. 1. The computed 
tomography (CT) and 
ultrasonographic find-
ings of the pre and post 
state of using ceftria-
xone in the case 1 pa-
tient. (A) There is no 
evidence of gallbladder 
(GB) stone on the initial 
CT scan. (B) A huge GB 
stone is seen on the 
follow-up CT scan after 
5 days of ceftriaxone 
usage. (C) A 2.5 × 3.5 cm 
GB stone with acoustic 
shadowing is noted on 
the ultrasonography. (D) 
The presumed GB stone 
has completely disap-
peared on the one mon-
th follow-up ultrasono-
graphy.
performed on the 8th hospital day, showed a newly devel-
oped huge GB stone without inflammation (Fig. 1B), and a 
2.5 × 3.5 cm sized GB stone with an acoustic shadow was 
observed on ultrasonography (Fig. 1C). The patient had no 
symptoms to suspect cholecystitis, and the ceftriaxone 
had already been stopped, so we decided to observe this 
stone and the patient was discharged. Follow-up ultra-
sonography that was performed one month later showed 
that there was no stones remained in the GB (Fig. 1D).
Case 2
A 22-year-old man visited the emergency department 
due to fever for two days with aggravated dyspnea. 
Coarse breath sounds with rales were noted in both lungs, 
and a pneumonic infiltration was observed on the chest 
X-ray and chest CT. Twelve days of intravenous ceftriax-
one (2 g i.v. q 24 hours) and seven days of clarythromycin 
(500 mg p.o. q 12 hours) was used to treat the pneumonia. 
Because the patient tolerated the antibiotics, he was not 
placed on bed rest and allowed to oral intake. The fol-
low-up chest CT was performed on the 17th hospital day 
and it showed a newly developed stone in the GB (Fig. 2A, 
B). The ultrasonography that was performed on the 28th 
hospital day showed sustained GB sludge (Fig. 2C). The 
patient had no abdominal symptoms and the dyspnea and 
fever had resolved, so he was discharged on the 30th hos-
pital day. The patient was readmitted to the hospital for 
follow-up and there was no more stone in the GB on the 
follow-up CT (Fig. 2D).
DISCUSSION
After usage of ceftriaxone, 60% of the drug is excreted 
into the urine and 40% of the drug is excreted into the bile 
in patients with normal renal function [4]. The mechanism 
of ceftriaxone associated GB sludge is as follows: the con-
centration of ceftriaxone in the GB can become 20 to 150 
times greater than that in the serum, and excretion of cef-
triaxone could disturb the excretion of the bile acids [5]. 
The concentration of ionized calcium in the bile is elevated 
and ceftriaxone can precipitate with calcium, like what oc-Ceftriaxone induced GB stone
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Fig. 2. The computed 
tomography (CT) scan 
and ultrasonographic fi-
ndings of the pre and 
post states of using ce-
ftriaxone in the case 2 
patients. (A) There is no 
stone in the gallbladder 
(GB). (B) A GB stone is 
observed on the follow- 
up CT scan after 12 days 
of ceftriaxone usage. (C) 
GB sludge is seen on the 
ultrasonography. (D) The 
presumed GB stone has 
disappeared on the last 
follow-up CT scan.
curs with bilirubin, and so ceftriaxone-associated biliary 
sludge is mainly composed of a calcium-ceftriaxone 
complex. Addition, ceftriaxone itself could affect the con-
tractility of the GB [6].
The incidence of ceftriaxone-associated sludge or pseu-
dolithiasis has been reported in 15 to 46% of the patients 
treated with ceftriaxone [1,7] in Korea, and the incidence 
was reported to be 30% (17 patients out of 57) of the pedia-
tric patients who were treated with ceftriaxone. Sludge 
can also occur in the urinary tract [1], but only a few of 
these patients suffer from symptoms [7]. However, some-
times even gallstone pancreatitis or acute cholecystitis can 
occur after ceftriaxone treatment [8]. The main risk factors 
for ceftriaxone-associated GB sludge or stone was high 
daily dosages (over 2 g daily) and a long term duration of 
drug therapy [1,7]. Hypercalcemia, fasting and total pa-
renteral nutrition, major surgery and dehydration can also 
cause this biliary sludge [9].
In general, biliary sludge can be expected to take 3 to 22 
days after beginning ceftriaxone therapy [2,10] and it may 
reversible upon discontinuation of the drug with a range 
of 2 to 63 days after the end of treatment [2]. The sludge 
may serve as the nidus for gallstone pathogenesis, and the 
sludge commonly appears as a hypoechoic layer without 
acoustic shadowing. In our cases, we confirm that there 
was no GB stone initially, and GB stone was detected at 8th 
day and 17th day, respectively, after the ceftriaxone was 
started. The ceftriaxone-associated GB stone completely 
disappeared 1 month after discontinuation of the drug. 
There was GB sludge and no stone for the ultrasono-
graphic findings of the 2nd case. This might be due to the 
interval between when this was first diagnosed via CT and 
the follow-up ultrasonography; the ceftriaxone had al-
ready been discontinued, so the stone may have resolved 
and became sludge.
In conclusion, GB stones can occur after ceftriaxone 
therapy and most of these resolved spontaneously after 
discontinuation of the drug. Clinicians, and especially sur-
geons, should aware of this complication and they should 
avoid unnecessary surgical interventions.
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